UroGen Pharma Ltd. (URGN)
Automate Your Wheel Strategy on URGN
With Tiblio's Option Bot, you can configure your own wheel strategy including URGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol URGN
- Rev/Share 1.9373
- Book/Share -0.9797
- PB -13.5148
- Debt/Equity -2.6895
- CurrentRatio 5.6471
- ROIC -0.5343
- MktCap 610463300.0
- FreeCF/Share -2.2646
- PFCF -5.6843
- PE -4.5356
- Debt/Assets 0.5046
- DivYield 0
- ROE -974.8662
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | URGN | H.C. Wainwright | Neutral | Buy | -- | $50 | June 16, 2025 |
| Downgrade | URGN | H.C. Wainwright | Buy | Neutral | -- | -- | May 22, 2025 |
| Initiation | URGN | Scotiabank | -- | Sector Outperform | -- | $23 | April 16, 2025 |
| Resumed | URGN | Ladenburg Thalmann | -- | Buy | -- | $31 | Feb. 19, 2025 |
| Initiation | URGN | Guggenheim | -- | Buy | -- | $40 | Aug. 22, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
Published: May 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN).
Read More
Investigation Alert: UroGen Pharma Ltd. (URGN) Under Scrutiny - Contact Levi & Korsinsky for Details
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Investors to Reach Out
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON UROGEN PHARMA LTD. (URGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On May 16,.
Read More
Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Potential Securities Fraud Allegations
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Stockholders to Reach Out
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
UroGen Pharma Ltd. (URGN) Investors Who Lost Money – Contact Law Offices of Howard G.
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UROGEN PHARMA LTD. (URGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by emai.
Read More
INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLC
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) complied with federal securities laws. On May 16, 2025, the FDA stated: “Given that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.” Following this news, the price of the Company's stock dropped.
Read More
UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2025 Earnings Conference Call May 12, 2025 10:00 AM ET Company Participants Vincent Perrone - Senior Director, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Chris Degnan - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Kelsey Goodwin - Guggenheim Leland Gershell - Oppenheimer Raghuram Selvaraju - H.
Read More
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Urogen Pharma (URGN) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.97 per share a year ago.
Read More
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent developments. “We are entering a pivotal and exciting period for UroGen as we approach the anticipated FDA approval of our lead pipeline product, UGN-102, in June for recurrent low-grade in.
Read More
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Urogen Pharma (URGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
Published: April 27, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achie.
Read More
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
Published: April 27, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without ne.
Read More
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Published: April 27, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen's sustained-release formulation of mitomycin being developed for the tre.
Read More
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
Published: April 26, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC). "The early safety profile and clinical activity results fro.
Read More
UroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call Transcript
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral
UroGen Pharma Ltd. (NASDAQ:URGN ) Q4 2024 - Earnings Conference Call March 10, 2025 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Michael Schmidt - Guggenheim Raghuram Selvaraju - H.
Read More
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Urogen Pharma (URGN) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.72 per share a year ago.
Read More
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality on the response to UGN-102, an investigational drug in development for treatment of LG-IR-NMIBC. Analyses of pre-specified subgroups showed comparable CR rates and DOR pa.
Read More
About UroGen Pharma Ltd. (URGN)
- IPO Date 2017-05-04
- Website https://www.urogen.com
- Industry Biotechnology
- CEO Ms. Elizabeth A. Barrett
- Employees 234